A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Anders Johnsson, Helga Hagman, Jan-Erik Frödin, Åke Berglund, N. Keldsen, Eva Fernebro, J Sundberg, R De Pont Christensen, K-L Garm Spindler, D Bergström, A Jakobsen

    Research output: Contribution to journalArticlepeer-review

    27 Citations (SciVal)

    Abstract

    The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).
    Original languageEnglish
    Pages (from-to)2335-2341
    JournalAnnals of Oncology
    Volume24
    Issue number9
    DOIs
    Publication statusPublished - 2013

    Subject classification (UKÄ)

    • Cancer and Oncology

    Fingerprint

    Dive into the research topics of 'A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.'. Together they form a unique fingerprint.

    Cite this